Ultimovacs (BATS-CHIXE:ULTIO) - Stock Price, News & Analysis

ULTIO Stock Overview

A biotech company, develops immunotherapies against cancers in Norway. More details

ULTIO fundamental analysis
Snowflake Score
Valuation	2/6
Future Growth	2/6
Past Performance	0/6
Financial Health	5/6
Dividends	0/6

Rewards

Revenue is forecast to grow 40.71% per year

Risk Analysis

Does not have a meaningful market cap (NOK78M)

Makes less than USD$1m in revenue (NOK0)

Shares are highly illiquid

Currently unprofitable and not forecast to become profitable over the next 3 years

+ 1 more risk

Ultimovacs ASA Competitors

Roquefort Therapeutics

LSE:ROQ

UK£5.6m

Genflow Biosciences

LSE:GENF

UK£6.1m

Aptamer Group

AIM:APTA

UK£6.5m

Cizzle Biotechnology Holdings

LSE:CIZ

UK£7.5m

Price History & Performance

Summary of all time highs, changes and price drops for Ultimovacs
Historical stock prices
Current Share Price	NOK 9.09
52 Week High	NOK 109.00
52 Week Low	NOK 100.20
Beta	0.98
11 Month Change	0%
3 Month Change	-2.15%
1 Year Change	-87.25%
33 Year Change	n/a
5 Year Change	n/a
Change since IPO	-87.25%

Recent updates

Shareholder Returns

	ULTIO	GB Biotechs	GB Market
7D	0%	2.0%	1.7%
1Y	-87.2%	-17.5%	8.3%

Return vs Industry: ULTIO underperformed the UK Biotechs industry which returned -22.4% over the past year.

Return vs Market: ULTIO underperformed the UK Market which returned 7.4% over the past year.

Price Volatility

Is ULTIO's price volatile compared to industry and market?
ULTIO volatility
ULTIO Average Weekly Movement	n/a
Biotechs Industry Average Movement	9.7%
Market Average Movement	4.8%
10% most volatile stocks in GB Market	10.3%
10% least volatile stocks in GB Market	2.6%

Stable Share Price: ULTIO has not had significant price volatility in the past 3 months.

Volatility Over Time: Insufficient data to determine ULTIO's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
2011	23	Carlos de Sousa	www.ultimovacs.com

Ultimovacs ASA, a biotech company, develops immunotherapies against cancers in Norway. Its lead product candidate is UV1, a peptide-based therapeutic cancer vaccine that induces a specific T cell response against the pan-tumor antigen telomerase. Ultimovacs ASA was incorporated in 2011 and is headquartered in Oslo, Norway.

Ultimovacs ASA Fundamentals Summary

How do Ultimovacs's earnings and revenue compare to its market cap?
ULTIO fundamental statistics
Market cap	NOK 77.76m
Earnings (TTM)	-NOK 179.27m
Revenue (TTM)	n/a

0.0x

P/S Ratio

-0.4x

P/E Ratio

Is ULTIO overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
ULTIO income statement (TTM)
Revenue	NOK 0
Cost of Revenue	NOK 0
Gross Profit	NOK 0
Other Expenses	NOK 179.27m
Earnings	-NOK 179.27m

Last Reported Earnings

Jun 30, 2024

Next Earnings Date

Nov 06, 2024

Earnings per share (EPS)	-5.21
Gross Margin	0.00%
Net Profit Margin	0.00%
Debt/Equity Ratio	0%

How did ULTIO perform over the long term?

See historical performance and comparison